Financial Performance - The company's operating revenue for the six months ended June 30, 2024, was RMB 4,732,481,467.24, representing a 1.29% increase compared to RMB 4,672,269,049.13 for the same period in 2023[8]. - Total profit for the same period was RMB 303,363,837.69, a decrease of 8.61% from RMB 331,945,812.26 in the previous year[8]. - Net profit attributable to shareholders of the listed company was RMB 265,404,417.68, down 1.63% from RMB 269,807,157.85 in the prior year[8]. - The net cash flow from operating activities increased significantly by 284.49%, reaching RMB 77,401,054.87 compared to RMB 20,131,070.66 in the previous year[8]. - Operating revenue for the first half of 2024 reached RMB 4,732,481,467.24, a 1.29% increase compared to RMB 4,672,269,049.13 in the same period of 2023[55]. - Operating costs increased by 8.13% to RMB 3,547,931,805.24 from RMB 3,281,046,254.21 year-on-year[55]. - The gross profit margin decreased by 4.75 percentage points to 25.03% from the previous year[58]. - The company reported a net profit of RMB 303,363,837.69 for the first half of 2024, down from RMB 532,685,725.02 in the same period of 2023[59]. - The total comprehensive income for the period was RMB 300,093,254.25, compared to RMB 289,553,439.14, reflecting an increase of about 3.5%[100]. - The company reported a total comprehensive income of RMB 238,097,470.11 for the first half of 2024, down from RMB 358,104,139.33 in the same period last year[101]. Shareholder Information - The company plans to distribute an interim dividend of RMB 0.25 per 10 shares, based on a total share capital of 682,407,635 shares[5]. - The total number of shareholders is 86,475, including 39 H-share shareholders and 86,436 A-share shareholders[13]. - The total number of shares as of June 30, 2024, is 682,407,635, with 94.34% being unrestricted shares[12]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.02% of the shares, totaling 204,864,092 shares[14]. - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 28.33% of the shares, totaling 193,314,147 shares[14]. - The number of restricted circulating shares is 38,633,274, accounting for 5.66% of the total share capital[12]. - The number of unrestricted circulating shares is 643,774,361, accounting for 94.34% of the total share capital[12]. - The shareholding structure shows no changes in the controlling shareholder or actual controller during the reporting period[18]. - The total salary paid to directors, supervisors, and senior management during the reporting period is RMB 2,011,825, with an additional RMB 6,390,878 for exercised stock options[22]. - The total number of A-shares held by directors, supervisors, and senior management is 2,055,050, representing approximately 0.4216% of the total issued A-shares[19]. Employee Information - The total number of employees in the group as of June 30, 2024, is 7,064, with a total salary expenditure of RMB 410,054,000 for the half-year period[23]. - The employee distribution by function includes 3,873 production personnel, 643 engineering technicians, and 940 sales personnel[24]. - The educational background of employees shows that 1,893 have a university degree or higher, while 2,328 have a college degree[25]. - The company has conducted 46 training sessions in the first half of 2024, with 2,321 participants, focusing on various professional skills and safety knowledge[25]. - The company has no retired employees or bonuses distributed during the reporting period[23]. Research and Development - The company launched 7 new formulation products in the first half of 2024, with 12 additional products in the pipeline[38]. - The company obtained 14 new product approvals and 6 consistency evaluation approvals in the first half of 2024[40]. - The company completed Phase I clinical trials for the innovative drug OAB-14 targeting Alzheimer's disease[40]. - Research and development expenses rose by 2.72% to RMB 231,912,142.60 compared to RMB 225,778,632.69 in the previous year[55]. - The company has established a roadmap for 91 innovation breakthrough projects for 2024[41]. - The company aims to accelerate the development of new products and market expansion, targeting the launch of at least 20 new products by the end of the year[47]. Financial Position - Total assets as of June 30, 2024, amounted to RMB 8,733,859,124.56, reflecting a 5.40% increase from RMB 8,286,166,330.90 at the end of 2023[8]. - Total liabilities increased by 7.09% to RMB 3,759,211,551.82 from RMB 3,510,413,044.14 at the end of 2023[8]. - The asset-liability ratio of the group stands at 43.04% as of June 30, 2024, reflecting a stable capital structure[61]. - The total capital debt ratio is 29.42% and the net capital debt ratio is 8.46%, indicating a manageable level of debt[61]. - The total current assets reached RMB 3,638,665,068.80, an increase from RMB 3,314,333,616.01 as of December 31, 2023, representing a growth of approximately 9.8%[94]. - The accounts receivable increased to RMB 1,022,661,555.32 from RMB 699,877,948.91, reflecting a growth of about 46.1%[94]. - The total equity attributable to shareholders increased to RMB 4,754,065,944.57 from RMB 4,553,103,869.56, showing an increase of about 4.41%[95]. - The total liabilities of the company at the end of June 2024 were RMB 2,122,924,920.24, an increase from RMB 2,000,000,000.00, reflecting a growth of approximately 6.1%[106]. Environmental Compliance - The company reported a total wastewater discharge with a chemical oxygen demand (COD) concentration of less than 500 mg/L, with a total COD discharge of 111 tons per year[78]. - The company has implemented pollution discharge standards for various pollutants, ensuring compliance with environmental regulations[78]. - The company operates in compliance with the environmental protection department's regulations as a key pollutant discharge unit[77]. - The company has established three wastewater treatment facilities with a total capacity of 12,000 tons per day, and additional facilities at subsidiaries with capacities of 500 tons and 3,000 tons per day, ensuring compliance with wastewater discharge standards[81]. - The company has developed emergency response plans for environmental incidents, including fire, explosion, and hazardous material leaks[86]. Corporate Governance - The company has maintained compliance with corporate governance standards as per relevant regulations in China[67]. - The company confirmed compliance with corporate governance codes without any deviations during the reporting period[88]. - The audit committee reviewed the unaudited interim accounts for the six months ending June 30, 2024, and agreed with the financial accounting principles adopted[89]. - The company has committed to avoiding any business or activities that may lead to competition or conflicts of interest with its main business during the period of control by its major shareholder[69]. - The company ensures that all transactions with its subsidiaries and related parties are conducted on an equal, voluntary, and fair basis[70]. Risk Management - The group has implemented measures to mitigate risks related to industry policy changes, new drug development, and raw material price fluctuations[64][65][66]. - The company is enhancing compliance management and risk control systems to ensure safe development[49]. - The company has established risk response mechanisms for potential disputes related to the "Quanding Huajun" project[72]. Investment and Financing - The company has no plans for share buybacks, sales, or repurchases during the reporting period[74]. - The company raised RMB 7,724,800.00 through stock options exercised in January 2024, contributing to the increase in registered capital[111]. - The company reported a profit of RMB 8,182,200 from its financial investments during the reporting period[75]. - The company has not planned any major investments or acquisitions for the upcoming years[87]. Revenue Recognition - The company recognizes revenue when control of goods or services is transferred to the customer, indicating a focus on sales of pharmaceutical products[188]. - Domestic sales revenue is recognized upon delivery of goods to customers, ensuring that payment rights are established and collectible[189]. - For export sales, revenue is recognized when products are customs cleared and the company has obtained the necessary shipping documents, confirming control transfer[190].

证券代码：000756 证券简称：新华制药 公告编号：2024-40 山东新华制药股份有限公司 关于获得《药品补充申请批准通知书》等相关情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药 品监督管理局核准签发的己酮可可碱注射液（以下简称"本品"）《药品补充申请批准通知书》， 批准本品上市许可持有人转让补充申请。现将相关情况公告如下： 一、基本情况 药品名称：己酮可可碱注射液 剂型：注射剂 注册分类：化学药品3类 申请人：山东新华制药股份有限公司 申请事项：上市许可持有人变更 受理号：CYHB2401223 药品批准文号：国药准字H20243881 通知书编号：2024B03985 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此次申请事 项符合药品注册的有关要求，同意按照《药品上市后变更管理办法（试行）》相关规定，批 准本品上市许可持有人变更。 二、其他相关信息 规格：5ml: 0.1g 药品分类：处方药 本次交易事项不构成关联交易，也不构成《上市公司重大 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 1 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited (於中華人民共和國註冊成立之股份有限公司) (股份編號：00719) | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000756 证券简称：新华制药 公告编号：2024-33 山东新华制药股份有限公司 2023年周年股东大会、2024年第一次A股类别股东会议及 2024年第一次H股类别股东会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 特别提示： 1、公司2023年周年股东大会（"周年股东大会"）、2024年第一次A股类别股东会议（"A股类别 股东会议"）、2024年第一次H股类别股东会议（"H股类别股东会议"，连同周年股东大会及A股类别 股东会议以下统称"会议"）有否决议案的情形。《关于提请股东大会授权董事会全权办理以简易程 序向特定对象发行股票具体事宜的议案》未获股东通过。 2、周年股东大会、A股类别股东会议、H股类别股东会议不涉及变更前次股东大会决议的情形。 一、会议召开的情况 1、召开时间： 5、主持人：本公司董事长贺同庆先生 6、周年股东大会、A股类别股东会议、H股类别股东会议的召开符合《中华人民共和国公司法》、 1 《深圳证券交易所上市公司股东大会网络投票实施细则》和本公司《公司章程》等有关规定。 二、会议的出席情况 | | 出席现场会议 ...

证券代码：000756 证券简称：新华制药 公告编号：2024-28 1、召开届次：2023 年度周年股东大会、2021 年第一次 A 股类别股东会议 2、召开时间 （1）现场会议召开时间 ①2023 年度周年股东大会：2024 年 6 月 26 日下午 2 时 ②2024 年第一次 A 股类别股东会议：2024 年 6 月 26 日下午 3 时（或紧随本公司 2023 年度周 年股东大会结束后） （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 6 月 26 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络 投票的时间为自 2024 年 6 月 26 日上午 9:15 至下午 15:00 期间的任意时间。 山东新华制药股份有限公司 关于召开 2023 年度周年股东大会、2024 年第一次 A 股类别股东会议的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 一、召开会议的基本情况 公司于 2024 年 4 月 25 日召开第十一届董事会第三次会议， ...

Financial Performance - Operating revenue for Q1 2024 was RMB 2,474,697,457.66, a decrease of 6.25% compared to RMB 2,639,665,769.78 in Q1 2023[2] - Net profit attributable to shareholders for Q1 2024 was RMB 141,879,437.62, down 6.41% from RMB 151,603,818.36 in Q1 2023[2] - Basic earnings per share for Q1 2024 were RMB 0.21, a decrease of 8.70% from RMB 0.23 in Q1 2023[3] - The total profit for Q1 2024 was RMB 168,771,522.02, compared to RMB 184,919,311.15 in Q1 2023, showing a decline in profitability[4] - Net profit attributable to the parent company was approximately $141.88 million, a decrease from $151.60 million in the previous period[5] - Total comprehensive income attributable to the parent company was approximately $142.69 million, compared to $159.49 million previously[5] - Basic earnings per share were $0.21, down from $0.23 in the prior period[5] - Total comprehensive income for the period was approximately $146.08 million, compared to $161.72 million previously[5] - Other comprehensive income after tax attributable to the parent company was approximately $807,373.60, down from $7.89 million previously[5] - The company reported a decrease in foreign currency translation adjustments, with a loss of approximately $(69,418.40)[5] Cash Flow and Assets - Net cash flow from operating activities improved significantly to RMB 38,063,364.43, compared to a negative RMB 183,742,803.27 in the same period last year, representing a 120.72% increase[2] - Total assets as of March 31, 2024, were RMB 8,467,977,386.18, reflecting a 2.19% increase from RMB 8,286,166,330.90 at the end of 2023[3] - Net assets attributable to shareholders increased by 4.65% to RMB 4,764,918,585.13 from RMB 4,553,103,869.56 at the end of 2023[3] Research and Development - Research and development expenses for Q1 2024 were RMB 141,905,763.44, compared to RMB 112,119,587.26 in Q1 2023, indicating a focus on innovation[4] Strategic Initiatives - The company plans to continue its market expansion and enhance product development strategies in the upcoming quarters[1] - The company continues to focus on strategic initiatives to enhance operational efficiency and market presence[5] Governance and Compliance - The board approved changes to accounting policies effective January 1, 2024, with no significant impact on the financial statements[6] - The company is committed to adhering to the new accounting standards as outlined by the Ministry of Finance[6] - The board of directors consists of a mix of executive and independent non-executive members, ensuring diverse governance[7] Profitability Metrics - The company reported a gross profit margin of approximately 5.89% for Q1 2024, down from 6.81% in Q1 2023[4]

Financial Performance - The financial summary for 2023 indicates that the company achieved a total revenue of RMB 1.5 billion, representing a year-on-year increase of 12%[14] - The net profit attributable to shareholders for the year was RMB 300 million, reflecting a growth of 15% compared to the previous year[14] - Operating income for 2023 reached RMB 8.1 billion, an increase of 7.97% compared to RMB 7.5 billion in 2022[17] - Total profits for 2023 amounted to RMB 532.7 million, reflecting a growth of 12.91% from RMB 471.8 million in the previous year[17] - Net profits attributable to shareholders of the listed company increased by 20.79% to RMB 496.5 million, up from RMB 411.1 million in 2022[17] - Basic earnings per share rose to RMB 0.74, representing a 19.35% increase from RMB 0.62 in 2022[17] - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year[14] - Net cash flow from operating activities decreased significantly by 65.01% to RMB 265.3 million, down from RMB 758.2 million in 2022[17] Market Expansion and Strategy - User data shows that the company expanded its customer base by 20%, reaching a total of 1.2 million active users[14] - The company has set a revenue target of RMB 1.8 billion for 2024, which would represent a growth of 20% year-on-year[14] - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2025[14] - A strategic acquisition of a local competitor is expected to enhance the company's production capacity by 25%[14] - New product development efforts have led to the launch of three innovative pharmaceutical products, contributing to 10% of total sales in 2023[14] Shareholder Information - The total number of issued shares as of December 31, 2023, was 674,682,835, an increase from 669,627,235 in 2022[30] - The top shareholder, Hualu Holdings Group Co. Ltd., held 30.36% of the shares, totaling 204,864,092 shares[43] - The second-largest shareholder, HKSCC (Nominees) Limited, held 28.65% of the shares, totaling 193,314,147 shares[43] - The top ten shareholders collectively held a significant portion of the company's shares, with no pledges or freezes reported[44] - The company had a total of 92,982 shareholders as of February 29, 2024, indicating a slight decrease in shareholder count[39] Governance and Management - The Company has a diverse board of directors with expertise in economics, law, finance, and pharmaceuticals, enhancing its strategic decision-making capabilities[74][75][80] - The Company is focused on expanding its market presence and enhancing its product offerings through strategic leadership and experienced management[72][78] - The management team is well-versed in financial operations, with the CFO, Mr. Hou Ning, having extensive experience in auditing and finance[75] - The board's composition reflects a commitment to governance and strategic oversight, essential for the Company's long-term success[78][82] - The Company has maintained a stable leadership structure with no significant changes reported during the year[103] Internal Control and Audit - The Audit Committee confirmed that the financial statements for 2023 were prepared in accordance with the accounting policies and standards, reflecting the company's assets, liabilities, and operating results accurately as of December 31, 2023[161] - Shine Wing issued a standard audit report without reservation, indicating that the financial statements accurately represent the company's financial condition and performance for 2023[170] - The company’s governance structure includes a Remuneration and Appraisal Committee, which operates under the guidelines of the Hong Kong Stock Exchange[175] - The internal control leading team is responsible for organizing and implementing internal control activities, reporting to the Board of Directors on the development and evaluation of internal control[195] - The effectiveness of internal control may change due to internal and external environmental factors, and the company has mechanisms in place to identify and rectify internal control deficiencies[200] Employee and Training Programs - As of December 31, 2023, the Group employed 7,104 staff with total wages amounting to RMB 743,778,000[128] - In 2023, the Company completed 71 corporate-level education training programs, training a total of 3,365 employees[137] - The Company has established a training system that enhances the capability and competency of staff members, ensuring efficient operation of the management system[139] - The Group's employee remuneration is determined based on national policies and the Company's financial condition, ensuring competitive compensation[128] Proposed Dividend - The proposed dividend for the year 2023 is RMB0.25 per share, subject to shareholder approval[63] - The Company is advised to exercise caution regarding the proposed dividend distribution, which may be adjusted based on changes in total issued share capital[63] - Further details regarding the proposed cash dividend will be disclosed in due course, including payment currency and applicable foreign exchange rate[64]

Financial Performance - The total operating revenue for 2023 reached RMB 8,100,844,707.33, representing a 7.97% increase from RMB 7,502,987,102.09 in 2022[3] - The net profit attributable to shareholders of the listed company was RMB 496,512,201.25, an increase of 20.79% compared to RMB 411,063,056.58 in the previous year[3] - The basic earnings per share for 2023 was RMB 0.74, reflecting a 19.35% increase from RMB 0.62 in 2022[3] - The company reported a total profit of RMB 532,685,725.02, compared to RMB 471,774,350.61 in 2022, marking an increase of 12.9%[42] - The company’s gross profit margin for the year was approximately 29.0%, calculated from total revenue and cost of goods sold[61] - The total tax and additional charges for 2023 were RMB 92,175,276.66, an increase from RMB 65,309,856.07 in 2022, reflecting a growth of approximately 41%[63] Assets and Liabilities - The total assets as of the end of 2023 amounted to RMB 8,286,166,330.90, showing a slight increase of 0.26% from RMB 8,264,790,395.98 in 2022[4] - The total liabilities decreased by 10.34% to RMB 3,510,413,044.14 from RMB 3,915,226,169.32 in the previous year[4] - Current assets totaled RMB 3,314,333,616.01, down from RMB 3,456,959,427.88 in the previous year, reflecting a decrease of approximately 4.1%[40] - The company’s total non-current assets increased to RMB 4,971,832,714.89 from RMB 4,807,830,968.10, reflecting a growth of approximately 3.4%[40] - The company’s equity attributable to shareholders increased to RMB 4,553,103,869.56 from RMB 4,126,274,379.52, indicating a growth of approximately 10.3%[41] Cash Flow - The cash flow from operating activities was RMB 265,278,895.87, a significant decrease of 65.01% compared to RMB 758,240,601.50 in 2022[3] - Operating cash inflow for 2023 was RMB 7,057,191,280.19, a decrease of 0.80% compared to 2022[22] - Net cash flow from operating activities decreased by 65.01% to RMB 265,278,895.87 due to increased customer payment terms and fulfillment of contracts from previous year[23] - Investment cash outflow increased by 32.84% to RMB 325,133,303.80, primarily due to increased project investments[23] - Financing cash inflow decreased by 25.51% to RMB 868,447,154.49, attributed to reduced fundraising from non-public A-share issuance and increased dividend payments[23] Shareholder Information - As of December 31, 2023, the total number of shareholders was 97,594, including 39 H-share shareholders and 97,555 A-share shareholders[7] - The largest shareholder, Hualu Holdings Group Co., Ltd., held 30.36% of the shares, totaling 204,864,092 shares[8] - The total number of shares issued by the company is 682,407,635, which includes 487,407,635 A shares and 195,000,000 H shares[11] - The proposed final dividend for the year 2023 is RMB 0.25 per share, subject to shareholder approval[11] - The weighted average number of ordinary shares outstanding increased to 674,287,215.00 in 2023 from 660,602,072.00 in 2022, representing a growth of about 2.9%[67] Operational Highlights - The company's main business involves the development, manufacturing, and sales of chemical raw materials, formulations, and pharmaceutical intermediates[15] - The company achieved a sales revenue growth of 48.73% in the formulation processing and export business year-on-year[27] - A total of 18 new products were launched in the market during the year, with 26 drug approvals and 15 veterinary drug approvals, setting a historical high[27] - The company successfully passed 195 quality audits and inspections, achieving zero quality incidents for the year[28] - The company has been recognized as a model factory for intelligent manufacturing and a leading enterprise in talent development in Shandong Province[28] Research and Development - R&D expenses increased by 21.29% to ¥419,239,700.90 from ¥345,658,511.77[20] - The company is focusing on enhancing the quality and reducing costs of pharmaceutical intermediates to support raw material drug development[30] - The company plans to accelerate the development of the EPA series and other specialty raw materials to achieve sales growth in both international and domestic markets[30] - The company aims to obtain over 10 formulation approvals, 3 raw material drug approvals, and 5 consistency evaluation approvals in 2024[30] Employee Information - The company reported a total employee count of 7,104 and total employee compensation of RMB 743,778 thousand for the year 2023[32] - The total provision for employee benefits increased significantly, reflecting the company's commitment to employee welfare and retention strategies[56] - Short-term employee compensation increased significantly from RMB 95,171,404.13 to RMB 123,985,296.73, reflecting higher labor costs or expanded workforce[55] Market and Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[44] - The company has implemented two equity incentive plans to enhance the motivation of management and core staff[29] - The company has established a green channel for new product transformation to expedite the market launch process[30]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 截至2023年9月30日止九個月之 未經審核季度業績公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》（「上市規則」）第13.09條及第13.10B條 以及《證券及期貨條例》（香港法例第571章）第XIVA部項下的內幕消息條文（定義見上市規則） 而作出。 山東新華製藥股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈本公司及其附屬公司（「本 集團」）截至2023年9月30日止九個月未經審核的綜合業績。本公告所載之財務資料均按照《中國企 業會計準則》（定義見上市規則）編製並經董事會及董事會審核委員會審視並核准。 本公司董事會、監事會及董事、監事、高級管理人員及主管會計工作負責人保證本公告內容的真實、 準確、完整 ...

山 東 新 華 製 藥 股 份 有 限 公 司 Shandong Xinhua Pharmaceutical Company Limited ( H 股股份代號：00719 ) (Ａ股股份代號：000756 ) 2023 中 期 報 告 目 錄 | --- | --- | |----------------------------------------------------|-------| | | | | 公司基本情況 | 2 | | 按《中國企業會計準則》編製的主要財務數據和財務指標 | 3 | | 股本變動及股東情況 | 6 | | 董事、監事、高級管理人員及員工情況 | 10 | | 董事長報告 | 22 | | 經營管理研討與分析 | 26 | | 重要事項 | 36 | | 公司管治 | 50 | | 財務報告 | 51 | | 備查文件 | 218 | 重要提示 本公司董事會、監事會及董事、監事、高級管理人員保證半年度報告內容的真實、準確、完整，不 存在虛假記載、誤導性陳述或重大遺漏，並承擔個別和連帶的法律責任。 本公司及其附屬公司（「本集團」）截至2023年6月30日止半年度財務報告未經審 ...